Details:
PHSU05 (ensereptide) is a synthetic peptide derived from human lactoferricin peptide, it inhibits the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- alpha, to prevent post-surgical adhesions and scar formation.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: PHSU05
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
PXL01 (ensereptide) is a synthetic peptide derived from human lactoferricin peptide, it inhibits the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- alpha, to prevent post-surgical adhesions and scar formation.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: PXL01
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
The company's ensereptide program is focused on the prevention of skin scarring in conjunction with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of tissue adhesions after hand and spine surgery.
Lead Product(s): Ensereptide
Therapeutic Area: Dermatology Product Name: PXL01
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Pergamum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2022
Details:
FOL-005 is a modified, short version of the endogenous protein, osteopontin. The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation.
Lead Product(s): FOL-005
Therapeutic Area: Dermatology Product Name: FOL-005
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. Patients themselves apply one of three different strengths of FOL-005 or placebo to the scalp once a day.
Lead Product(s): FOL-005
Therapeutic Area: Dermatology Product Name: FOL-005
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The Phase 2 AFFIRM-35 trial in patients with moderate-to-severe psoriasis has shown excellent and sustained clinical response in patients. Based on these encouraging clinical results, clinical development program of ABY-035 has been expanded to include further indications.
Lead Product(s): ABY-035
Therapeutic Area: Dermatology Product Name: ABY-035
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
In two previous clinical studies, FOL-005 administered as an intradermal injection has been shown to be an effective and safe treatment for stimulation of hair growth.
Lead Product(s): FOL-005
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020